Open Label, Multicenter, Real World Treatment Study of Single Agent Tagrisso; KOREA PLUS Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS)

At a glance
Trial Overview
Trial Details
Interventions
Trial Centres
- Centres
Trial History
References

Trial Profile

Open Label, Multicenter, Real World Treatment Study of Single Agent Tagrisso; KOREA PLUS Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 27 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Osimertinib (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions
Acronyms KOREA-PLUS
Sponsors AstraZeneca

Most Recent Events

25 Nov 2024 Status changed from recruiting to completed.
22 Aug 2024 Planned End Date changed from 30 Jun 2024 to 31 Oct 2024.
22 Aug 2024 Planned primary completion date changed from 30 Jun 2024 to 31 Oct 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com